These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 20659558)

  • 1. Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice.
    Melrose HL; Dächsel JC; Behrouz B; Lincoln SJ; Yue M; Hinkle KM; Kent CB; Korvatska E; Taylor JP; Witten L; Liang YQ; Beevers JE; Boules M; Dugger BN; Serna VA; Gaukhman A; Yu X; Castanedes-Casey M; Braithwaite AT; Ogholikhan S; Yu N; Bass D; Tyndall G; Schellenberg GD; Dickson DW; Janus C; Farrer MJ
    Neurobiol Dis; 2010 Dec; 40(3):503-17. PubMed ID: 20659558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. G2019S LRRK2 enhances the neuronal transmission of tau in the mouse brain.
    Nguyen APT; Daniel G; Valdés P; Islam MS; Schneider BL; Moore DJ
    Hum Mol Genet; 2018 Jan; 27(1):120-134. PubMed ID: 29088368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice.
    Yue M; Hinkle KM; Davies P; Trushina E; Fiesel FC; Christenson TA; Schroeder AS; Zhang L; Bowles E; Behrouz B; Lincoln SJ; Beevers JE; Milnerwood AJ; Kurti A; McLean PJ; Fryer JD; Springer W; Dickson DW; Farrer MJ; Melrose HL
    Neurobiol Dis; 2015 Jun; 78():172-95. PubMed ID: 25836420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Behavioral deficits and striatal DA signaling in LRRK2 p.G2019S transgenic rats: a multimodal investigation including PET neuroimaging.
    Walker MD; Volta M; Cataldi S; Dinelle K; Beccano-Kelly D; Munsie L; Kornelsen R; Mah C; Chou P; Co K; Khinda J; Mroczek M; Bergeron S; Yu K; Cao LP; Funk N; Ott T; Galter D; Riess O; Biskup S; Milnerwood AJ; Stoessl AJ; Farrer MJ; Sossi V
    J Parkinsons Dis; 2014; 4(3):483-98. PubMed ID: 25000966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Behavioral, neurochemical, and pathologic alterations in bacterial artificial chromosome transgenic G2019S leucine-rich repeated kinase 2 rats.
    Lee JW; Tapias V; Di Maio R; Greenamyre JT; Cannon JR
    Neurobiol Aging; 2015 Jan; 36(1):505-18. PubMed ID: 25174649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's disease.
    Tozzi A; Durante V; Bastioli G; Mazzocchetti P; Novello S; Mechelli A; Morari M; Costa C; Mancini A; Di Filippo M; Calabresi P
    Neurobiol Dis; 2018 Oct; 118():1-8. PubMed ID: 29908325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S.
    Li X; Patel JC; Wang J; Avshalumov MV; Nicholson C; Buxbaum JD; Elder GA; Rice ME; Yue Z
    J Neurosci; 2010 Feb; 30(5):1788-97. PubMed ID: 20130188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of exacerbation of neurodegeneration in a double transgenic mouse model of mutant LRRK2 and tau.
    Mikhail F; Calingasan N; Parolari L; Subramanian A; Yang L; Flint Beal M
    Hum Mol Genet; 2015 Jun; 24(12):3545-56. PubMed ID: 25804954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice.
    Longo F; Mercatelli D; Novello S; Arcuri L; Brugnoli A; Vincenzi F; Russo I; Berti G; Mabrouk OS; Kennedy RT; Shimshek DR; Varani K; Bubacco L; Greggio E; Morari M
    Acta Neuropathol Commun; 2017 Mar; 5(1):22. PubMed ID: 28292328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2.
    Ramonet D; Daher JP; Lin BM; Stafa K; Kim J; Banerjee R; Westerlund M; Pletnikova O; Glauser L; Yang L; Liu Y; Swing DA; Beal MF; Troncoso JC; McCaffery JM; Jenkins NA; Copeland NG; Galter D; Thomas B; Lee MK; Dawson TM; Dawson VL; Moore DJ
    PLoS One; 2011 Apr; 6(4):e18568. PubMed ID: 21494637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake.
    Zhou H; Huang C; Tong J; Hong WC; Liu YJ; Xia XG
    Int J Biol Sci; 2011; 7(6):753-61. PubMed ID: 21698001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology progression.
    Lubben N; Brynildsen JK; Webb CM; Li HL; Leyns CEG; Changolkar L; Zhang B; Meymand ES; O'Reilly M; Madaj Z; DeWeerd D; Fell MJ; Lee VMY; Bassett DS; Henderson MX
    Transl Neurodegener; 2024 Mar; 13(1):13. PubMed ID: 38438877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiologically relevant factors influence tau phosphorylation by leucine-rich repeat kinase 2.
    Hamm M; Bailey R; Shaw G; Yen SH; Lewis J; Giasson BI
    J Neurosci Res; 2015 Oct; 93(10):1567-80. PubMed ID: 26123245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. (G2019S) LRRK2 causes early-phase dysfunction of SNpc dopaminergic neurons and impairment of corticostriatal long-term depression in the PD transgenic mouse.
    Chou JS; Chen CY; Chen YL; Weng YH; Yeh TH; Lu CS; Chang YM; Wang HL
    Neurobiol Dis; 2014 Aug; 68():190-9. PubMed ID: 24830390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LRRK2 Facilitates tau Phosphorylation through Strong Interaction with tau and cdk5.
    Shanley MR; Hawley D; Leung S; Zaidi NF; Dave R; Schlosser KA; Bandopadhyay R; Gerber SA; Liu M
    Biochemistry; 2015 Aug; 54(33):5198-208. PubMed ID: 26268594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered Development of Synapse Structure and Function in Striatum Caused by Parkinson's Disease-Linked LRRK2-G2019S Mutation.
    Matikainen-Ankney BA; Kezunovic N; Mesias RE; Tian Y; Williams FM; Huntley GW; Benson DL
    J Neurosci; 2016 Jul; 36(27):7128-41. PubMed ID: 27383589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptional responses to loss or gain of function of the leucine-rich repeat kinase 2 (LRRK2) gene uncover biological processes modulated by LRRK2 activity.
    Nikonova EV; Xiong Y; Tanis KQ; Dawson VL; Vogel RL; Finney EM; Stone DJ; Reynolds IJ; Kern JT; Dawson TM
    Hum Mol Genet; 2012 Jan; 21(1):163-74. PubMed ID: 21972245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LRRK2 G2019S mutation induces dendrite degeneration through mislocalization and phosphorylation of tau by recruiting autoactivated GSK3ß.
    Lin CH; Tsai PI; Wu RM; Chien CT
    J Neurosci; 2010 Sep; 30(39):13138-49. PubMed ID: 20881132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anatomical localization of leucine-rich repeat kinase 2 in mouse brain.
    Melrose H; Lincoln S; Tyndall G; Dickson D; Farrer M
    Neuroscience; 2006; 139(3):791-4. PubMed ID: 16504409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity.
    Nguyen APT; Tsika E; Kelly K; Levine N; Chen X; West AB; Boularand S; Barneoud P; Moore DJ
    Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17296-17307. PubMed ID: 32631998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.